Wheaton Franciscan Healthcare-Saint Francis/Reiman Cancer Center
Welcome,         Profile    Billing    Logout  
 10 Trials 
172 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Taylor, James G
NCT04451408: A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

Active, not recruiting
1
224
Japan, US
LY3372993, Placebo
Eli Lilly and Company
Alzheimer Disease, Healthy
11/24
11/24
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
Kirshner, Jeffrey J
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
Choi, Young Min
NCT05051332: Phase 3 Clinical Trial of CartiLife® in Korea

Active, not recruiting
3
104
RoW
Autologous Chondrocyte Implantation (CartiLife®), CartiLife, Microfracture Surgery
Biosolution Co., Ltd.
Articular Cartilage Defect, Articular Cartilage Degeneration
09/23
09/24
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
3
804
Europe, US, RoW
Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
12/26
12/26
NCT04060394: Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Completed
1/2
49
US, RoW
Phase I and Phase II: LAE001/prednisone + afuresertib, Phase II: Afuresertib
Laekna Limited
Metastatic Castration-resistant Prostate Cancer
12/23
03/24
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Active, not recruiting
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
01/26
01/26
HyperlynX, NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN

Terminated
1
18
Europe, US, RoW
Xevinapant, Debio 1143, Cisplatin, intensity-modulated radiation therapy (IMRT)
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
DENEX HTN-KORAS, NCT04307836: DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Recruiting
N/A
140
RoW
Renal Denervation
Kalos Medical
Hypertension, Vascular Diseases, Cardiovascular Diseases
07/23
04/24
NCT04747834: Assessment of Low Energy Lens Fragmentation Cataract Extraction in Patients Undergoing Cataract Surgery

Completed
N/A
100
US
MICOR-304
Carl Zeiss Meditec, Inc., Carl Zeiss Meditec Cataract Technology, Inc.
Cataract
01/22
01/22
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
08/23
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
Mucopolysaccharidosis II, NCT05058391: A Study of Elaprase in Children and Adults With Hunter Syndrome () in India

Active, not recruiting
4
4
RoW
Elaprase, Idursulfase
Takeda
Hunter Syndrome
04/24
10/24
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Active, not recruiting
4
50
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
03/26
03/26
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
06/27
06/27
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
51
Europe, Japan, US
BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Active, not recruiting
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
03/25
03/25
NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
NCT06165341: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Recruiting
3
50
Europe, Canada, US
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo
Takeda
Alpha1-Antitrypsin Deficiency
08/28
08/28
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Recruiting
3
34
Europe, US, RoW
von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease
01/25
01/25
NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
TAK-935-3004, NCT06422377: A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Terminated
3
1
Europe
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
08/24
08/24
NCT04974749: A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

Completed
3
20
RoW
REPLAGAL, Agalsidase Alfa, TAK-675
Takeda
Fabry Disease
01/24
01/24
NCT05460325: A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Completed
3
20
RoW
Lanadelumab, SHP643, TAKHZYRO, TAK-743, DX-2930, Lanadelumab Injection
Takeda
Hereditary Angioedema (HAE)
11/23
11/23
Vedolizumab-3041, NCT06443502: A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Not yet recruiting
3
30
Europe, RoW
Vedolizumab, Entyvio, MLN0002, Kynteles, Concomitant Antibiotic Therapy
Takeda
Pouchitis
12/29
12/29
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06060067 / 2023-000134-15: A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India

Recruiting
3
480
RoW
TDV, TAK-003, Placebo
Takeda, Takeda
Healthy Volunteers
11/24
04/25
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
NCT05529992 / 2022-002323-35: A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Active, not recruiting
3
20
RoW
Velaglucerase Alfa, VPRIV
Takeda, Takeda
Gaucher Disease
08/24
08/24
NCT05707351: A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Completed
3
37
RoW
Adynovate, Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol
Takeda
Hemophilia A
09/24
09/24
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Not yet recruiting
3
20
RoW
Maribavir, TAK-620
Takeda
Cytomegalovirus (CMV)
02/27
02/27
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
NCT04701411 / 2020-003193-48: A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease

Recruiting
3
20
Europe, Japan, RoW
Darvadstrocel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
06/25
12/25
ACTION-1, NCT05477576: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
MLN0002-3024, NCT04779307 / 2020-004300-34: A Study of Vedolizumab in Children and Teenagers with Moderate to Severe Ulcerative Colitis (UC)

Active, not recruiting
3
121
Europe, Canada, Japan, US, RoW
Vedolizumab, MLN0002, ENTYVIO, KYNTELES
Takeda, Takeda Development Center Americas, Inc.
Colitis, Ulcerative
08/25
08/25
NCT04759833: A Study of Prucalopride For Functional Constipation in Children and Teenagers

Terminated
3
175
US
Prucalopride, TAK-555, Prucalopride succinate, Placebo
Takeda, Takeda Development Center Americas, Inc.
Constipation
11/23
11/23
NCT05156983: A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Recruiting
3
328
Europe, Canada, US
TAK-330, SOC 4F-PCC
Takeda, Takeda Development Center Americas, Inc.
Coagulation Disorder
04/28
04/28
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Recruiting
3
400
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
05/26
05/26
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting
3
77
Europe, Japan, US, RoW
TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930
Takeda, Takeda Development Center Americas, Inc., Shire
Thrombotic Thrombocytopenic Purpura (TTP)
03/27
03/27
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

Active, not recruiting
3
80
Europe, Japan, US, RoW
Maribavir, TAK-620
Takeda, Takeda Development Center Americas, Inc.
Cytomegalovirus (CMV)
01/27
01/27
NCT04969731: Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer

Recruiting
3
408
RoW
Immuncell-LC, Autologous activated T lymphocyte, Gemcitabine
GC Cell Corporation
Pancreatic Ductal Adenocarcinoma
12/26
06/27
PACES, NCT01349881: S0820, Adenoma and Second Primary Prevention Trial

Active, not recruiting
3
354
US
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
SWOG Cancer Research Network, National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Colorectal Neoplasms
02/27
02/32
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
NCT06076642: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Recruiting
3
39
US
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., SC Investigational Needle Sets
Takeda, Takeda Development Center Americas, Inc., Baxalta Innovations GmbH, now part of Takeda
Primary Immunodeficiency Diseases (PID)
01/29
01/29
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
NCT05442567 / 2021-000630-34: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Recruiting
3
240
Europe, Canada, Japan, US, RoW
Vedolizumab IV, MLN0002, ENTYVIO, KYNTELES, No Intervention
Takeda, Takeda Development Center Americas, Inc.
Ulcerative Colitis, Crohn's Disease
08/31
08/31
NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Recruiting
2/3
75
Europe, US, RoW
TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20.
Takeda, Takeda Development Center Americas, Inc.
Primary Immunodeficiency Diseases (PID)
02/26
09/26
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT06031259: Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment

Recruiting
2/3
8
Europe, Canada
Idursulfase-IT, Elaprase
Takeda
Hunter Syndrome
01/34
06/34
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Recruiting
2
90
Canada, US, RoW
Placebo, TAK-101, Gluten
Takeda
Celiac Disease
10/25
10/25
ALTITUDE-AD, NCT06335173: A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease

Recruiting
2
540
Europe, Canada, US
sabirnetug, Placebo
Acumen Pharmaceuticals
Alzheimer Disease
10/26
10/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
NCT05814016: A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Terminated
2
41
US
Danavorexton, TAK-925, Placebo
Takeda
Sleep Apnea
09/24
09/24
NCT05469802: A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults

Withdrawn
2
78
US
Purified Inactivated Zika Virus Vaccine (PIZV), TAK-426, Placebo
Takeda
Healthy Volunteers
07/24
07/24
NCT04278924 / 2019-004103-12: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

Completed
2
41
Europe, Japan, US, RoW
Placebo, TAK-079
Takeda
Primary Immune Thrombocytopenia
04/24
04/24
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting
2
186
US
Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited
CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
10/24
06/25
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
NCT02616302 / 2014-004506-15: A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Recruiting
2
70
Europe, Canada, US, RoW
Dexlansoprazole, Dexilant
Takeda
Gastroesophageal Reflux Disease (GERD)
10/27
10/27
S2007, NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting
2
44
US
Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy
SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
12/27
12/28
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Active, not recruiting
2
40
Europe, US, RoW
TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930
Takeda, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
03/25
03/25
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Active, not recruiting
2
357
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
05/25
05/25
NCT05673785: A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Recruiting
2
52
RoW
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Prednisone
Takeda
Lymphoma
07/25
12/27
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Active, not recruiting
2
159
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
07/25
07/25
NCT05890352: Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recruiting
2
227
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Tazemetostat, E7438, EPZ-6438, EPZ6438, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
SWOG Cancer Research Network, National Cancer Institute (NCI), BeiGene, Ipsen, Incyte Corporation
Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
12/26
01/29
NCT02615184 / 2014-004507-73: A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old

Recruiting
2
76
Europe, Canada, US, RoW
Dexlansoprazole, Dexilant
Takeda
Erosive Esophagitis
10/27
10/27
LUNG-MAP SUB-STUDY, NCT06031688: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Recruiting
2
56
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2, Tepotinib, c-Met Inhibitor MSC2156119J, EMD 1214063, EMD-1214063, EMD1214063, MSC2156119J
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, EMD Serono
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
05/28
05/29
TAK-007-2001, NCT05020015: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Active, not recruiting
2
27
US
TAK-007, Chemotherapy Agents
Takeda
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
10/25
06/30
NCT04776018: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
1/2
27
Canada, US
TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Takeda
Relapsed and/or Refractory Multiple Myeloma (RRMM)
08/23
11/23
NCT04157517: A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Completed
1/2
45
US, RoW
Modakafusp Alfa, TAK-573, Pembrolizumab
Takeda
Neoplasms, Melanoma
11/23
11/23
iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1/2
336
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda
Multiple Myeloma
02/24
11/24
TRACY-1, NCT06590857: Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs

Recruiting
1/2
172
US
RYZ101, Pembrolizumab
RayzeBio, Inc.
Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
05/28
07/29
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Completed
1/2
11
Europe, US, RoW
Ponatinib, Ponatinib AAF, Chemotherapy Agents
Takeda, Takeda Development Center Americas, Inc.
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
12/23
07/24
COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Recruiting
1/2
182
Europe, Canada, US, RoW
TAK-280
Takeda, Takeda Development Center Americas, Inc.
Unresectable Locally Advanced or Metastatic Cancer
02/25
07/26
iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Completed
1/2
15
Europe, Canada, US, RoW
Modakafusp Alfa, TAK-573, Daratumumab
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
05/24
05/24
NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
313
US
TAK-500, Pembrolizumab
Takeda
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
08/26
08/26
EXCLAIM, NCT02716116 / 2016-001271-68: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Checkmark Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021
May 2021 - May 2021: Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021
Checkmark For EGFR Exon20 insertion+ metastatic 2L NSCLC
Jan 2021 - Jan 2021: For EGFR Exon20 insertion+ metastatic 2L NSCLC
Active, not recruiting
1/2
334
Europe, Japan, US, RoW
TAK-788, AP32788
Takeda
Carcinoma, Non-Small-Cell Lung
03/25
03/25
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Recruiting
1/2
258
Europe, US, RoW
TAK-186, MVC-101
Takeda
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
09/25
11/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
49
Europe, Japan, US, RoW
TAK-981, Pembrolizumab
Takeda, Takeda Development Center Americas, Inc.
Advanced or Metastatic Solid Tumors
11/25
11/25
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
53
US
GDX012, Chemotherapy Agents
Takeda
Leukemia
04/26
06/27
NCT04964258: A Study of TAK-105 in Healthy Adults

Completed
1
80
US
TAK-105-a, TAK-105-a Placebo
Takeda
Healthy Volunteers
06/23
06/23
 

Download Options